PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome.

TO THE EDITOR: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a rare aggressive malignancy in adults. BCP-ALL is frequently characterized by recurrent chromosomal translocations that deregulate proto-oncogenes or result in fusion genes encoding chimeric oncoproteins.[1][1] Gene

[1]  H. Dombret,et al.  Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Dombret,et al.  Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. , 2017, Blood.

[3]  J. Tchinda,et al.  Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia? , 2017, Blood advances.

[4]  Heather L. Mulder,et al.  Deregulation of DUX4 and ERG in acute lymphoblastic leukemia , 2016, Nature Genetics.

[5]  B. Johansson,et al.  Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia , 2016, Nature Communications.

[6]  Shinichi Morishita,et al.  Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults , 2016, Nature Genetics.

[7]  C. Mullighan,et al.  Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. , 2015, Blood.

[8]  J. Downing,et al.  PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia. , 2015, Blood.

[9]  M. Stratton,et al.  RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia , 2014, Nature Genetics.

[10]  M. Farrar,et al.  Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia , 2013, Genes & development.

[11]  Markus Jaritz,et al.  The B‐cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis , 2012, The EMBO journal.

[12]  R. Kuiper,et al.  The Origin and Nature of Tightly Clustered BTG1 Deletions in Precursor B-Cell Acute Lymphoblastic Leukemia Support a Model of Multiclonal Evolution , 2012, PLoS genetics.

[13]  J. D. Vos,et al.  PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study , 2009, Leukemia.

[14]  H. Dombret,et al.  Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[16]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[17]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[18]  C. Garvie,et al.  Structural studies of Ets-1/Pax5 complex formation on DNA. , 2001, Molecular cell.

[19]  Stephen L. Nutt,et al.  Commitment to the B-lymphoid lineage depends on the transcription factor Pax5 , 1999, Nature.

[20]  F. Sigaux,et al.  An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions , 2014, Leukemia.

[21]  M. Busslinger,et al.  Pax5: a master regulator of B cell development and leukemogenesis. , 2011, Advances in immunology.